GlobeNewswire: Bellerophon Therapeutics, Inc. Contains the last 10 of 99 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:13:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/06/05/2681822/0/en/Bellerophon-Announces-Top-Line-Data-from-Phase-3-REBUILD-Clinical-Trial-of-INOpulse-for-Treatment-of-Fibrotic-Interstitial-Lung-Disease.html?f=22&fvtc=4&fvtv=32576Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease2023-06-05T11:00:00Z<![CDATA[WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD).]]>https://www.globenewswire.com/news-release/2023/05/15/2669391/0/en/Bellerophon-Provides-Clinical-Program-Update-and-Reports-First-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=32576Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results2023-05-15T20:50:35Z<![CDATA[WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023.]]>https://www.globenewswire.com/news-release/2023/05/11/2666738/0/en/Bellerophon-Therapeutics-Announces-Last-Patient-Has-Completed-Blinded-Treatment-in-Phase-3-REBUILD-Study-for-INOpulse-in-Fibrotic-Interstitial-Lung-Disease.html?f=22&fvtc=4&fvtv=32576Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease2023-05-11T12:30:42Z<![CDATA[Pivotal top-line data readout expected in mid-2023 Pivotal top-line data readout expected in mid-2023]]>https://www.globenewswire.com/news-release/2023/03/31/2638625/0/en/Bellerophon-Provides-Clinical-Program-Update-and-Reports-Full-Year-2022-Financial-Results.html?f=22&fvtc=4&fvtv=32576Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results2023-03-31T12:30:00Z<![CDATA[WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022.]]>https://www.globenewswire.com/news-release/2023/03/06/2621122/0/en/Bellerophon-Therapeutics-Announces-5-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=32576Bellerophon Therapeutics Announces $5 Million Registered Direct Offering2023-03-06T13:30:00Z<![CDATA[WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. The offering is expected to close on March 7, 2023, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/02/09/2605021/0/en/Bellerophon-Therapeutics-Receives-IND-Clearance-from-China-NMPA-to-Conduct-Phase-3-Clinical-Trial-in-China-for-INOpulse-in-Fibrotic-Interstitial-Lung-Disease.html?f=22&fvtc=4&fvtv=32576Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease2023-02-09T13:30:00Z<![CDATA[China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint]]>https://www.globenewswire.com/news-release/2023/01/18/2591328/0/en/Bellerophon-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-REBUILD-Study-for-INOpulse-in-Fibrotic-Interstitial-Lung-Disease.html?f=22&fvtc=4&fvtv=32576Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease2023-01-18T21:05:42Z<![CDATA[Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023]]>https://www.globenewswire.com/news-release/2023/01/05/2583730/0/en/Bellerophon-Therapeutics-Announces-License-Agreement-for-the-Commercialization-of-INOpulse-in-Greater-China-with-Baylor-BioSciences.html?f=22&fvtc=4&fvtv=32576Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences2023-01-05T13:30:00Z<![CDATA[Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China]]>https://www.globenewswire.com/news-release/2022/11/14/2555042/0/en/Bellerophon-Provides-Clinical-Program-Update-and-Reports-Third-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=32576Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results2022-11-14T13:30:00Z<![CDATA[Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023]]>https://www.globenewswire.com/news-release/2022/09/27/2523327/0/en/Bellerophon-Announces-FDA-Acceptance-of-Change-to-Ongoing-Phase-3-REBUILD-Study-of-INOpulse-for-Treatment-of-Fibrotic-Interstitial-Lung-Disease.html?f=22&fvtc=4&fvtv=32576Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease2022-09-27T12:30:00Z<![CDATA[WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD). The new study size of 140 subjects does not impact the trial’s principal objective or endpoints and maintains power of >90% (p-value < 0.01) for the primary endpoint of Moderate to Vigorous Physical Activity (MVPA) based on the effect size observed in Phase 2.]]>